Status:
COMPLETED
AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study
Lead Sponsor:
Duke University
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
50-85 years
Brief Summary
The purpose of this study is to identify whether changes in age-related macular degeneration (AMD) over time as seen with spectral domain optical coherence tomography (SDOCT) imaging, can be used to p...
Detailed Description
The primary objective of this study is to identify whether SDOCT patterns such as: drusen size, OCT reflectivity within drusen, photoreceptor (PR)change over drusen, microfoci of subretinal fluid (SRF...
Eligibility Criteria
Inclusion
- AMD subjects and controls
- Men and women between the ages of 50 and 85 years
- AMD subjects
- Enrollment in the AREDS 2 trial;
- Macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye
Exclusion
- Ocular media not clear enough to allow good fundus photography.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
470 Patients enrolled
Trial Details
Trial ID
NCT00734487
Start Date
June 1 2008
End Date
August 1 2015
Last Update
October 14 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Eye Center
Atlanta, Georgia, United States, 30322
2
National Eye Institute
Bethesda, Maryland, United States, 20892
3
Duke University Eye Center
Durham, North Carolina, United States, 27705
4
Devers Eye Center
Portland, Oregon, United States, 97210